Login to Your Account

That's 'ALS' She Wrote: Biogen Phase III Another Bust in Space

By Randy Osborne
Staff Writer

Thursday, January 3, 2013
With most investor eyes focused on the waited-for FDA approval of Biogen Idec Inc.'s BG-12 for early stage multiple sclerosis (MS), the market hardly flinched at news that dexpramipexole failed in a Phase III trial for amyotrophic lateral sclerosis (ALS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription